BioDelivery Sciences International, Inc. (BDSI)

Mar 22, 2021 - BDSI was delisted (reason: acquired by Collegium Pharmaceutical)
5.59
-0.00 (-0.09%)
Last trade price
-0.09%
Market Cap 577.05M
Revenue (ttm) 166.70M
Net Income (ttm) 84.86M
Shares Out 103.23M
EPS (ttm) 0.82
PE Ratio 6.82
Forward PE 15.06
Dividend n/a
Ex-Dividend Date n/a
Volume 2,107,479
Open 5.60
Previous Close 5.60
Day's Range n/a
52-Week Range 2.50 - 5.62
Beta 0.56
Analysts Buy
Price Target 5.48 (-2.0%)
Earnings Date May 4, 2022

About BDSI

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally ... [Read more...]

Industry Pharmaceuticals
Founded 1997
CEO Jeffrey Bailey
Employees 200
Stock Exchange NASDAQ
Ticker Symbol BDSI
Full Company Profile

Financial Performance

In 2021, BDSI's revenue was $166.70 million, an increase of 6.54% compared to the previous year's $156.47 million. Earnings were $84.86 million, an increase of 230.05%.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for BDSI stock is "Buy." The 12-month stock price forecast is 5.48, which is a decrease of -1.97% from the latest price.

Price Target
$5.48
(-1.97% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Has BioDelivery Sciences International (BDSI) Outpaced Other Medical Stocks This Year?

Here is how BioDelivery Sciences International (BDSI) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.

6 months ago - Zacks Investment Research

Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

7 months ago - Zacks Investment Research

BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults

7 months ago - GlobeNewsWire

BIODELIVERY SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates ...

NEW ORLEANS, Feb. 16, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

7 months ago - PRNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioDelivery Sciences International, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - February 15, 2022) - Rigrodsky Law, P.A. is investigating BioDelivery Sciences International, Inc. ("BioDelivery") (NASDAQ: BDSI) regarding possible breaches of f...

7 months ago - Newsfile Corp

SHAREHOLDER ALERT: WeissLaw LLP Investigates BioDelivery Sciences International, Inc.

NEW YORK, Feb. 15, 2022 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioDelivery Sciences International, Inc...

Other symbols: COLL
7 months ago - PRNewsWire

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.

7 months ago - Zacks Investment Research

BDSI Stock Alert: The Deal Sending Little-Known BioDelivery Skyrocketing Today

Today, a big takeover announcement has sent shares of BioDelivery and BDSI stock soaring more than 50% on investor enthusiasm for this deal. The post BDSI Stock Alert: The Deal Sending Little-Known BioD...

7 months ago - InvestorPlace

Merger Mania Is Sending These 2 Little-Known Stocks Soaring

Markets opened lower on Monday morning, but nothing held these two companies back.

Other symbols: CNR
7 months ago - The Motley Fool

BDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is F...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) to Collegium Pharmaceutical, Inc. f...

7 months ago - Business Wire

3 Potential Value Opportunities to Consider

When seeking value opportunities, investors could be interested in the following stocks, since their prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based disco...

Other symbols: CUROHOFT
7 months ago - GuruFocus

Shareholder Alert: Ademi LLP investigates whether BioDelivery Sciences International, Inc. has obtained a Fair Price ...

MILWAUKEE, Feb. 14, 2022 /PRNewswire/ -- Ademi LLP is investigating BioDelivery Sciences (NASDAQ: BDSI) for possible breaches of fiduciary duty and other violations of law in its transaction with Colleg...

7 months ago - PRNewsWire

Collegium Pharma Broadens Its Pain Portfolio With $600M BioDelivery Sciences Deal

Collegium Pharmaceutical Inc (NASDAQ: COLL) will acquire BioDelivery Sciences International Inc (NASDAQ: BDSI) at $5.60 per share in an all-cash transaction, corresponding to an equity value of approxim...

Other symbols: COLL
7 months ago - Benzinga

BioDelivery's stock rockets toward a 2-year high after buyout deal with Collegium at a 54% premium

Shares of BioDelivery Sciences International Inc. BDSI, -1.62% blasted 51.7% higher to pace all premarket gainers Monday, after the specialty pharmaceutical company with a portfolio of pain and neurolog...

7 months ago - Market Watch

Collegium to Acquire BioDelivery Sciences in an All-Cash Deal

Transaction is valued at $5.60 per share representing a total equity value of $604 million

7 months ago - GlobeNewsWire

Why the Earnings Surprise Streak Could Continue for BioDelivery (BDSI)

BioDelivery (BDSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

7 months ago - Zacks Investment Research

Should Value Investors Pick BioDelivery (BDSI) Stock Now?

Let's see if BioDelivery (BDSI) stock is a good choice for value-oriented investors right now from multiple angles.

7 months ago - Zacks Investment Research

Why Shares of BioDelivery Sciences International Jumped 12.2% on Monday

Shares of the small pharmaceutical company, which focuses on pain management, have been rising since it released updated guidance late last week.

8 months ago - The Motley Fool

BioDelivery (BDSI) Stock Up on Raised Guidance for 2021

BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.

8 months ago - Zacks Investment Research

Why BioDelivery Sciences International Stock Was Up 28.5% Monday

The biotech company received a favorable court ruling regarding its lead therapy.

9 months ago - The Motley Fool

BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032

RALEIGH, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex...

9 months ago - GlobeNewsWire

Why Is BioDelivery (BDSI) Down 20.8% Since Last Earnings Report?

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?

9 months ago - Zacks Investment Research

BioDelivery Sciences International (BDSI) Tops Q3 Earnings Estimates

BioDelivery (BDSI) delivered earnings and revenue surprises of 16.67% and -2.28%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

BioDelivery Sciences Reports Solid Third Quarter 2021 Results

Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year

10 months ago - GlobeNewsWire